A Target Product Profile (TPP) for an agitation treatment for people living with dementia

There is a huge unmet need for effective and safe treatments for the symptoms of dementia and Alzheimer’s disease to help patients and carers today and into the future. To help stimulate investment and interest in developing new treatments for people living with dementia, together with Alzheimer’s Research UK we have co-developed a Target Product Profile (TPP) and an economic model for agitation in Alzheimer’s disease.

The launch of the target product profile and economic model will be accompanied by a live webinar on 18th January, 13.30-15.00 (GMT), online via Zoom, jointly hosted by Alzheimer’s Research UK and Medicines Discovery Catapult’s Psychiatry Consortium, during which the models will be presented to the audience, followed by a live Q&A.

Register your place for free >